RAF–MEK–ERK pathway inhibitors are used to treat cancers exhibiting BRAFV600E mutations, but drug resistance commonly develops. Here, analysis of patient-derived xenograft (PDX) of BRAFV600E-mutant cancers and single-cell DNA sequencing showed that following drug treatment, parallel evolutionary tracts enable the selection and

中文翻译：

---

抗癌药：抗药性

RAF–MEK–ERK途径抑制剂可用于治疗具有BRAFV600E突变的癌症，但通常会产生耐药性。在这里，对源自BRAFV600E突变型癌症的患者异种移植物（PDX）的分析和单细胞DNA测序表明，在药物治疗后，平行的进化途径可以选择和